Mast Cell Activation Syndrome (MCAS) Treatments
Find Mast Cell Activation Syndrome (MCAS) Treatments
Medications for Mast Cell Activation Syndrome (MCAS)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mast Cell Activation Syndrome (MCAS).
Found 2 Approved Drugs for Mast Cell Activation Syndrome (MCAS)
Imatinib
Brand Names
Gleevec, Imkeldi
Imatinib
Brand Names
Gleevec, Imkeldi
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: May 15, 2001
Classification: Kinase Inhibitor
Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Ayvakit
Generic Name
Avapritinib
Ayvakit
Generic Name
Avapritinib
Form: Tablet
Method of administration: Oral
FDA approval date: January 09, 2020
Classification: Kinase Inhibitor
AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances